XenoPort, Inc. (Nasdaq:XNPT) announced today that it will present data
on XP23829, an investigational prodrug of monomethyl fumarate (MMF), at
the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston. Data being presented
include the results from a clinical trial evaluating the safety,
tolerability and pharmacokinetics of XP23829.
The title of the poster, presentation time and location are as follows:
|
XP23829
|
|
• Steady state pharmacokinetics and blood lymphocyte responses
in healthy subjects dosed with XP23829, a novel fumaric acid ester
for multiple sclerosis;
|
|
Poster 958; Friday, September 12, 2014; 2:45 p.m. ET
|
|
Location: Hall C, Poster Exhibition area, 2nd Floor, Hynes
Convention Center
|
About XP23829
XP23829, an experimental drug discovered and currently under development
by XenoPort, is a fumaric acid ester compound that is a prodrug of MMF.
XenoPort is currently evaluating XP23829 in a Phase 2 clinical trial as
a potential treatment for moderate-to-severe chronic plaque-type
psoriasis, and XP23829 may be a potential treatment for relapsing forms
of multiple sclerosis (MS).
XP23829 is protected by a composition-of-matter patent that currently
has an expiration date of 2029.
About XenoPort
XenoPort, Inc. is a biopharmaceutical company focused on developing and
commercializing a portfolio of internally discovered product candidates
for the potential treatment of neurological disorders. XenoPort is
currently commercializing HORIZANT® (gabapentin enacarbil)
Extended-Release Tablets in the United States and developing its novel
fumaric acid ester product candidate, XP23829, as a potential treatment
for patients with moderate-to-severe chronic plaque-type psoriasis
and/or relapsing forms of MS. REGNITE® (gabapentin enacarbil)
Extended-Release Tablets is being marketed in Japan by Astellas Pharma
Inc. XenoPort recently granted exclusive world-wide rights for the
development and commercialization of its clinical-stage oral product
candidate, arbaclofen placarbil, to Reckitt Benckiser Pharmaceuticals,
Inc. for all indications. XenoPort's pipeline of product candidates also
includes a potential treatment for patients with Parkinson's disease.
To learn more about XenoPort, please visit the website at www.XenoPort.com.
Forward-Looking Statements
This press release contains “forward-looking” statements, including,
without limitation, all statements related to advancing the development
of XP23829; the suitability of XP23829 as a potential treatment for
moderate-to-severe chronic plaque-type psoriasis and/or relapsing forms
of MS; and the therapeutic and commercial potential of XP23829. Any
statements contained in this press release that are not statements of
historical fact may be deemed to be forward-looking statements. Words
such as “may,” “potential,” “will” and similar expressions are intended
to identify forward-looking statements. These forward-looking statements
are based upon XenoPort's current expectations. Forward-looking
statements involve risks and uncertainties. XenoPort's actual results
and the timing of events could differ materially from those anticipated
in such forward-looking statements as a result of these risks and
uncertainties, which include, without limitation: the difficulty and
uncertainty of pharmaceutical product development and the uncertain
results and timing of clinical trials and other studies; XenoPort’s
ability to successfully conduct clinical trials in the anticipated
timeframes, or at all; the risk that XP23829 will require significant
additional clinical testing prior to any possible regulatory approvals
and failure could occur at any stage of its development; the uncertainty
of the regulatory review process and other regulatory requirements; the
uncertainty of protecting and expanding XenoPort's intellectual property
rights, including the risk that patent rights may not provide XenoPort
with sufficient protection against competitive products or otherwise
cover commercially valuable products or processes; XenoPort's dependence
on potential future collaborative partners; and the uncertain
therapeutic and commercial value of XenoPort's product candidates. These
and other risk factors are discussed under the heading “Risk Factors” in
XenoPort’s Quarterly Report on Form 10-Q for the quarter ended June 30,
2014 filed with the Securities and Exchange Commission on August 7,
2014. XenoPort expressly disclaims any obligation or undertaking to
release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in the company's
expectations with regard thereto or any change in events, conditions or
circumstances on which any such statements are based.
HORIZANT, REGNITE and XENOPORT are registered trademarks of XenoPort,
Inc.
XNPT2G
Copyright Business Wire 2014